The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer
Open accessAbstract
Human cancer cells operate a variety of effective molecular and signaling mechanisms which allow them to escape host immune surveillance and thus progress the disease. We have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9 are involved in the immune escape of human acute myeloid leukemia (AML) cells. These cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway. We hypothesized that the Tim-3-galectin-9 pathway may be involved in the immune escape of cancer cells of different origins. We found that studied breast tumors expressed significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues of the same patients and that these proteins were co-localized. Increased levels of LPHN2 and expressions of LPHN3 as well as FLRT3 were also detected in breast tumor cells. Activation of this pathway facilitated the translocation of galectin-9 onto the tumor cell surface, however no secretion of galectin-9 by tumor cells was observed. Surface-based galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3 and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range of human cancer cells and is possibly involved in prevention of anti-tumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
In vitro immunotherapy potency assays using real-time cell analysis
Cerignoli, F., Abassi, Y. A., Lamarche, B. J., Guenther, G., Santa Ana, D., Guimet, D., Zhang, W., Zhang, J., & Xi, B. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193498 · Cited by 105 · cited 2×
“Intriguingly, in line with our observations that galectin-9 levels in PC3 prostate cancer cells are low compared to other cancer cells, these cells were recently reported to be rapidly killed by TALL-104 cells used in our work (32).”
Background
Cited by
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Salcher, S., Sturm, G., Horvath, L., Untergasser, G., Kuempers, C., Fotakis, G., Panizzolo, E., Martowicz, A., Trebo, M., Pall, G., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.008 · Cited by 477
Metadata
- Authors
- Yasinska, I. M., Sakhnevych, S. S., Pavlova, L., Teo Hansen Selnø, A., Teuscher Abeleira, A. M., Benlaouer, O., Gonçalves Silva, I., Mosimann, M., Varani, L., Bardelli, M., Hussain, R., Siligardi, G., Cholewa, D., Berger, S. M., Gibbs, B. F., Ushkaryov, Y. A., Fasler-Kan, E., Klenova, E., & Sumbayev, V. V.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-11
- Volume
- 10
- Pages
- 1594-1594
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2957946774
- Cited by
- 177
- References
- 2
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. https://app.cochat.ai/papers/10.3389/fimmu.2019.01594
- The paper
- Yasinska, I. M., Sakhnevych, S. S., Pavlova, L., Teo Hansen Selnø, A., Teuscher Abeleira, A. M., Benlaouer, O., Gonçalves Silva, I., Mosimann, M., Varani, L., Bardelli, M., Hussain, R., Siligardi, G., Cholewa, D., Berger, S. M., Gibbs, B. F., Ushkaryov, Y. A., Fasler-Kan, E., Klenova, E., & Sumbayev, V. V. (2019). The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.01594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.